Loading
Latest filing published 02 Mar 2023 for Landos Biopharma, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Josep Bassaganya-Riera discloses dealings in Landos Biopharma, Inc. to SEC (Form 4). Over a trading history stretching from 29 November 2021 to 28 February 2023, the count stands at 26 filings.
On the market, this insider has only sold: 21 sales, €2.7M in total. The totals do not cover 5 filings with an undisclosed amount. In 2023 alone, the filings show no purchases and 5 sales.
The record was last updated on 2 March 2023 with an open-market sale in Landos Biopharma, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations